Capricor Therap (CAPR) Stock Price, Quote & News

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 727 1755

Website: www.capricor.com

Address:

10865 Road to the Cure, Suite 150, San Diego, United States

Termite1611 May. 13 at 11:45 AM

$CAPR H.C. Wainwright maintains $60 target and buy on capr.

0 · Reply

Parsnip May. 13 at 11:07 AM

$CAPR If Capricor provided documentation supporting their claims that NS went pencil down to Skadden and I’m rather certain they did because Skadden would have not taken the case under a he said she said dialogue. This is a very easy case to win for Capricor based on bargaining in good faith . NS will walk because they don’t want a drill down on their actions.

0 · Reply

wkee May. 13 at 11:05 AM

$CAPR sitting back now calm after Linda spoke yesterday!! it has been so much work and determination from Linda! She is an excellent CEO. She had a dream and she's making it come true for the DMD boys and their families !! Thanks to Linda she is not a quitter. She is determined talented successful scientist !

1 · Reply

NYTony May. 13 at 10:45 AM

$CAPR Regarding Linda's statement on the call about repaying NS the 50MM in payments received, i cannot remember but did CAPR give NS shares or dud NS purchase those shares? If given, If CAPR pays back the 50MM, NS shoukd at least transfer back 50MM worth of shares. An argument can be made that if there is a recession and you are returning the parties to their pre agreement position, NS should transfer all of the shares that were given and not purchased.

4 · Reply

Chitty123 May. 13 at 9:58 AM

$CAPR Consistently

0 · Reply

Alexandre_300 May. 13 at 9:23 AM

$CAPR setup after the Q1 call — my notes, not financial advice: Key points I’m watching: * Deramiocel in DMD with potential FDA approval * labeling discussions expected in the near future * CAPR seeking to recover U.S. rights — this seemed even stronger after the call * potential direct launch path * proprietary in-house manufacturing * possible expansion into younger DMD patients * Becker muscular dystrophy * Europe/Japan regulatory path * therapeutic exosomes * potential PRV Possible M&A premium? 🤔 To me, this no longer looks like just a single-product DMD story. It is starting to look like a potential rare neuromuscular + exosome platform story. Could be disruptive in the future if approval, launch execution, legal outcome, and platform expansion all line up.

0 · Reply

RAULINVEST May. 13 at 8:31 AM

$CAPR 3. Science is Undeniable (HOPE-3 Data) The Phase 3 data is "the most compelling in DMD history." Cardiac: 91% slowing of disease progression. Upper Limb: 54% reduction in severity. MRI Data: New data shows it actually stops the progression of cardiac fibrosis (the leading cause of death in DMD). 4. Financial Fortress Cash Runaway: $278M in cash keeps the lights on through Q4 2027. The PRV Goldmine: Upon approval, they get a Priority Review Voucher worth $100M+ in non-dilutive cash.

0 · Reply

RAULINVEST May. 13 at 8:30 AM

$CAPR My take of the strong call: 1. FDA is Moving FAST on Approval (PDUFA: Aug 22) The most bullish news was that Capricor is already in active labeling discussions with the FDA. Even better: the FDA is working with them on a temporary label solution so Capricor can start manufacturing and freezing commercial doses now. This is a massive signal that the Agency expects to approve the drug. 2. Taking the "Whole Pie" (Bye-Bye Nippon) Instead of a 30-40% royalty, Capricor is moving to capture 100% of the revenue. Linda confirmed she has been "laying the groundwork quietly for months" to launch solo. New Leadership: Hired a top-tier Chief Commercial Officer with deep DMD experience. New Partners: Confirmed they are in talks with a new distributor and expect a deal "very quickly."

0 · Reply

Skyhigh77 May. 13 at 8:25 AM

$CAPR $CAPR so almost a week hast past and NS has still not publicly objected the claims in a matter that Capricor has stated in the lawsuit… they put out a statement but not detailing anything which could mean they somehow know they’ve been caught in the act… hopefully they realize that the deal is dead and can come to a settlement…. Capricor has stated that they are willing to repay what they have received so far in milestones which I don’t fully agree they should do since we gave them shares in the company that since gone up significantly and they have made way more money then they originally put in… and they still have those shares at least what we’ve heard… hopefully we get a fast resolution of this case and move on after eventual approval… what everyone needs to do now including analysts that follows the company is to reevaluate the future sale projection and put out a new estimated SP if the Capr goes at it alone…mind blowing projections incoming 🤯😅👌more bullish then ever!

0 · Reply

LongLongStock May. 13 at 7:38 AM

$CAPR would be funny if hte new commercial officer is doug. I am joking. but that thought came across my head

0 · Reply

Capricor Therapeutics Earnings Call Transcript: Q1 2026

2026-05-12T20:09:36.000Z - 15 hours ago

Capricor Therapeutics options imply 9.4% move in share price post-earnings

May 12, 2026, 4:05 PM EDT - 15 hours ago

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

2026-05-08T18:58:25.000Z - 4 days ago

Capricor files suit against NS Pharma over Deramiocel distribution deal

May 4, 2026, 4:05 PM EDT - 8 days ago

Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

2026-03-20T12:45:14.000Z - 7 weeks ago

Capricor Therapeutics price target raised to $43 from $41 at Roth Capital

2026-03-13T18:35:53.000Z - 2 months ago

Capricor selloff today a buying opportunity, says Roth Capital

2026-03-13T16:01:07.000Z - 2 months ago

Capricor Therapeutics price target raised to $51 from $48 at Alliance Global

2026-03-13T12:27:39.000Z - 2 months ago

Capricor Therapeutics price target raised to $63 from $50 at B. Riley

2026-03-13T12:02:13.000Z - 2 months ago

Capricor Therapeutics price target raised to $58 from $45 at Piper Sandler

Mar 12, 2026, 4:30 PM EDT - 2 months ago

Capricor Therapeutics Earnings Call Transcript: Q4 2025

2026-03-12T20:16:10.000Z - 2 months ago

Capricor Therapeutics reports Q4 EPS (62c), consensus (55c)

Mar 12, 2026, 4:01 PM EDT - 2 months ago

Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

2026-03-12T19:16:07.000Z - 2 months ago

Capricor Therapeutics options imply 4.2% move in share price post-earnings

2026-03-12T13:15:17.000Z - 2 months ago

Capricor announces additional analyses, outcomes from Phase 3 HOPE-3 trial

Mar 12, 2026, 9:00 AM EDT - 2 months ago

Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy

2026-03-10T13:38:59.000Z - 2 months ago

Capricor announces establishment of new PDUFA date for dermiocel BLA

Mar 10, 2026, 9:25 AM EDT - 2 months ago

Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA

2026-01-20T14:25:31.000Z - 4 months ago

Capricor expects to submit updates to BLA in February 2026

Dec 17, 2025, 1:00 PM EST - 5 months ago

Capricor Therapeutics Transcript: Study Result

2025-12-15T13:20:28.000Z - 5 months ago

Capricor Therapeutics price target raised to $50 from $21 at B. Riley

2025-12-10T11:51:19.000Z - 5 months ago

Capricor Therapeutics price target raised to $45 from $20 at Piper Sandler

2025-12-08T13:46:18.000Z - 5 months ago

Capricor Therapeutics management to meet with Oppenheimer

2025-12-08T12:55:05.000Z - 5 months ago

Capricor Therapeutics price target raised to $54 from $22 at Oppenheimer

Dec 4, 2025, 4:01 PM EST - 5 months ago

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Dec 3, 2025, 11:30 AM EST - 5 months ago

Capricor Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 8:00 AM EST - 5 months ago

Capricor Therapeutics Transcript: Status Update

Dec 3, 2025, 7:44 AM EST - 5 months ago

Capricor's muscle disorder cell therapy succeeds in late-stage study

Nov 10, 2025, 4:30 PM EST - 6 months ago

Capricor Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 9:15 AM EST - 6 months ago

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

Oct 31, 2025, 9:15 AM EDT - 6 months ago

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

Oct 3, 2025, 10:45 AM EDT - 7 months ago

Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Sep 25, 2025, 8:30 AM EDT - 8 months ago

Capricor Therapeutics Transcript: Study Update

Sep 25, 2025, 7:15 AM EDT - 8 months ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

Sep 9, 2025, 9:20 AM EDT - 8 months ago

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

Aug 11, 2025, 4:30 PM EDT - 9 months ago

Capricor Therapeutics Earnings Call Transcript: Q2 2025

Aug 8, 2025, 8:30 AM EDT - 9 months ago

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

Aug 6, 2025, 9:00 AM EDT - 9 months ago

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

Jul 14, 2025, 4:14 PM EDT - 10 months ago

Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors

Jul 11, 2025, 4:53 PM EDT - 10 months ago

Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura

Jul 11, 2025, 8:30 AM EDT - 10 months ago

Capricor Therapeutics Transcript: Study Update

Jul 11, 2025, 6:36 AM EDT - 10 months ago

US FDA declines to approve Capricor's muscle disorder therapy

Jul 11, 2025, 6:30 AM EDT - 10 months ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

Jun 24, 2025, 9:16 AM EDT - 11 months ago

US FDA will not convene expert panel for Capricor Therapeutics' DMD cell therapy

Jun 20, 2025, 9:25 AM EDT - 11 months ago

Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy

Jun 17, 2025, 9:00 AM EDT - 11 months ago

Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program

Termite1611 May. 13 at 11:45 AM

$CAPR H.C. Wainwright maintains $60 target and buy on capr.

0 · Reply

Parsnip May. 13 at 11:07 AM

0 · Reply

wkee May. 13 at 11:05 AM

1 · Reply

NYTony May. 13 at 10:45 AM

4 · Reply

Chitty123 May. 13 at 9:58 AM

$CAPR Consistently

0 · Reply

Alexandre_300 May. 13 at 9:23 AM

0 · Reply

RAULINVEST May. 13 at 8:31 AM

0 · Reply

RAULINVEST May. 13 at 8:30 AM

0 · Reply

Skyhigh77 May. 13 at 8:25 AM

0 · Reply

LongLongStock May. 13 at 7:38 AM

$CAPR would be funny if hte new commercial officer is doug. I am joking. but that thought came across my head

0 · Reply

teddan80 May. 13 at 6:39 AM

$CAPR @quito_yume can you do your calculations again assuming we run without NS, for 250 and 2500 patients

1 · Reply

alwaysbuylate May. 13 at 6:26 AM

$CAPR @quito_yume i think it's time to create a version b (going alone) of your estimated stock price sheet!

0 · Reply

braindonor May. 13 at 6:19 AM

$CAPR Dr Hemmati agrees with me. How about you?

1 · Reply

lujpi May. 13 at 4:50 AM

$CAPR Dilution inc.

4 · Reply

StillFishing May. 13 at 4:35 AM

$CAPR Every additional billion in market cap is worth roughly $17 with today’s shares outstanding…. Around 58M I believe.. We’re sitting just below $2M right now at $31…. If we go at it alone we could see $10B without label expansion…. $6B would be pretty conservative…. You can do the math on the price per share! Let me know if my math is off…

1 · Reply

HamBoneXoXo May. 13 at 3:44 AM

$CAPR Major revelations just in case you were sleep 🤪😜😉 https://seekingalpha.com/article/4903556-capricor-therapeutics-inc-capr-q1-2026-earnings-call-transcript

5 · Reply

Jorlev May. 13 at 3:24 AM

$CAPR CAPRICOR Full Complaint against NS PHARMA/NIPPON SHINYAKU here..... https://www.sec.gov/Archives/edgar/data/1133869/000110465926057221/capr-20260507xex99d2.htm

1 · Reply

dnfrs May. 13 at 3:09 AM

$CAPR Interesting post by Dr. Hemmati about what the next FDA Commissioner should stand for. First of all...bring back the ADCOMS!... https://x.com/houmanhemmati/status/2054333081092579455

1 · Reply

dnfrs May. 13 at 2:58 AM

$CAPR After Deramiocel is approved for DMD in the US, and the marketing issue is solved...what is next? Linda said... "Our first target will likely be expansion to the younger DMD patients we are working on now. In addition, we plan to initiate the clinical pathway for Becker muscular dystrophy, which we plan to begin discussing with the FDA immediately following PDUFA for DMD. Expansion of deramiocel outside the United States is also underway, and we expect to meet with the EMA and PMDA later this year. We believe deramiocel should be available to all patients worldwide, and that will be a goal that we actively work towards this year. In addition, we're evaluating opportunities in other rare neuromuscular diseases where inflammation and fibrosis are the primary pathologies." Look to partnering with Big Pharma to reach "patients worldwide" and StealthX exosome therapeutics enter the clinic next year!

1 · Reply

OfficialStocktwitsUser May. 13 at 2:44 AM

$CAPR RSI: 41.12, MACD: 0.0434 Vol: 1.49, MA20: 33.63, MA50: 31.75 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Wealthy500 May. 13 at 2:39 AM

$SLS $CADL $CING $CAPR Time for biotech.

2 · Reply

HamBoneXoXo May. 13 at 2:37 AM

$CAPR NS: “Capricor’s claims lack merit” https://www.nippon-shinyaku.co.jp/english/ir/ir_news.php?id=3696

2 · Reply

Market Cap	1.85B
Revenue (ttm)	0.00
Net Income (ttm)	-105.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	3,645.60
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,056,400
Avg Vol	1,337,848
Day's Range	N/A - N/A
Shares Out	57.84M
Stochastic %K	50%
Beta	0.48
Analysts	Strong Sell
Price Target	$54.67